A 9-wk-old infant with familial giant cell hepatitis and severe intrahepatic cholestasis had low plasma concentrations of chcnodeoxycholic acid and cliolic acid and elcvatcd plasma conccntrations of 5P-cholestane-3a,7a, 12a,25-tetrol, 5P-cholestane-3 a , 7 a , 12a,24 7a,. Analysis of the urine by fast atom bombardment mass spcctromctry and by gas chromatography-mass spectromctry after treatmcnt with Hrlixpon~atin glucuronidase/sulfatase showed that the major cholanoids in urine were the glucuronidcs of 5P-cholcstane-3a,7a, 12a,24S,25-pentol, SP-cholestane-3a,7a,12a,25-tctrol, and 5P-cholcsta1ie-3cu,7a, 12a,24(-tetrol. Thcse results are consistent with an inborn crror of the 25-hydroxylase pathway for bile acid synthesis, specifically one of the enzymes responsihlc for conversion of 5P-cholestane-3a,7a,12a,24S,25-pentol 
patients with cholestasis have high plasma concentrations (3) . The site of the defect was determined by identifying the unusual metabolites in the urine followed by appropriate enzymology (4) . Treatment with chenodeoxycholic acid led to a dramatic improvement providing support for the hypothesis that deficiency of primary bile acids was an important factor in the cholestasis and malabsorption (2, (5) (6) (7) . Other inborn errors of bile acid synthesis have been described (2) . CTX leads to the excretion of large amounts of bile alcohol glucuronides in the urine (8) . Patients with CTX do not suffer from neonatal cholestasis perhaps because, although the 27-hydroxylase pathway for side chain oxidation is blocked, some cholic acid can be synthesized by the alternative 25-hydroxylation pathway for side chain oxidation (8-10) (see Fig. 1 ). [ In this report the 25-pro-R methyl group of cholesterol has been designated C26 and the 25-pro-S methyl group C27. Using this convention the mitochondria1 w-hydroxylase involved in bile acid synthesis is a 27-hydroxylase (9) .] This study describes an additional infant with familial cholestasis and low plasma concentrations of chenodeoxycholic acid and cholic acid. Analysis of the cholanoids (bile acids and alcohols) in the urine revealed that he was excreting large amounts of the glucuronides of S~-cholestane-3a,7a,12a,24S,25-pentol, 5P-cholestane-3a,7a,l2a,25-tetrol, and 5P-cholestane3a,7a,12a,24[-tetrol. These findings are compatible with an inborn error affecting conversion of SP-cholestane-3a,7a,l2a-trio1 to cholic acid via SP-cholestane-3a,7a,l2a,25-tetrol and 5P-cholestane-3cr,7a,12a,24S,25-pentol-the 25-hydroxylase pathway of side chain oxidation described by Shefer et al. (10) . Specifically, it suggests a defect in the conversion of 5P-cholestane-3cr,7a,12a,24S,25-pentol to cholic acid and acetone.
METHODS

Materials
Materials used for analysis of plasma bile acids by GC-MS (11) (12) (13) (14) and for analysis of urinary cholanoids by FAB-MS (3, 14, 15) have been described previously. For analysis of urinary bile alcohols by GC-MS, P-glucuronidase/sulfatase from Helix pomatia was obtained from Sigma Chemical Co. Ltd. (Poole, Dorset, UK).
Reference compounds. SP-Cholestane-3a,7cr,12a-triol was a gift from Dr. I Bjorkhem (Karolinska Institute, Huddinge, Sweden). 5P-Cholestane-3a,7a,l2a,25-tetrol and 5 Pcholestane-3a,7a,l2a,25(,26-pentol were from the Medical Research Council steroid reference collection. SP-Cholestane3a,7a,12a,24(-tetrol, SP-cholestane-3a,7a,l2a,24R,25-pentol, and SP-cholestane-3a,7~~,12a,24S,25-pentol were kindly provided by Prof. J. Sjovall (Karolinska Institute, Stockholm, Sweden). An additional sample of the 24s pentol was generously donated by Prof. G. Salen and Dr. B. Dayal (University of Medicine and Dentistry, Newark, NJ). (25R)-5P-Cholestan3a,7a,12a,27-tetrol was synthesized by reduction of methyl (25R)-3a,7a,12a-trihydroxy-~-cholestanoate using LiAlH, in diethyl ether. 5-Cholestene-3P,7a-diol (7a-hydroxycholesterol), S-cholestene-3P,7P-diol (7P-hydroxycholesterol), 3a,12a-dihydroxy-24-nor-5P-cholan-23-oic acid (nordeoxycholic acid), and methyl 3a,l2a-dihydroxy-SPcholanoate (methyl deoxycholate) were from Steraloids Inc. (Wilton, NH). TMS ethers for GC-MS analysis were prepared by heating (60°C, 1 h) in TriSil (Pierce, Rockford, IL). Samples were injected in reagent. Retention indices of reference compounds are in Table 1 . Mass spectra have been documented (16-21).
Analyses
Plasma cholanoid analysis. Plasma bile acids were analyzed by GC-MS using previously described methods (11-14) with minor modifications. Nor-deoxycholic acid was used as internal standard instead of 3a-hydroxy-7-oxo-5~-cholanoic acid, and toluene was used in place of benzene in the alumina chromatography stage of the assay. Analysis of quality control samples showed that these changes had no effect on quantitation of plasma bile acids. Reference ranges for plasma bile acid concentrations in normal and cholestatic infants have been documented previously (3, 12) .
Analysis of cholanoids in urine. Urine was analyzed by FAB-MS after extraction on octadecylsilane-bonded silica cartridges (3, 15) . The urine was then further analyzed by GC-MS after hydrolysis of bile alcohol sulfates and glucuronides with 5P-Cholestane-3a,7a,l2a-triol Methyl 3a,l2a-dihydroxy SP-cholanoate (methyl deoxycholatet) 5-Cholestene-3p,7P-diol (7P-hydroxycholestcrol) 5p-Cholestane-3a,7a0(12a,24 [-tetrol 5P-Cholestanc-3a,7a,l2a,25-tetrol (25R)-SP-Cholestanc-3a,7aCY12a,27-tetrol SP-Cholestane-3a,7aO112a,24R,25-pentol 5P-Cholestane-3a,7aOI12a,24S,2S-pentol 5P-Cholestane-3a,7aLY 12a,2%,26-pcntol
Internal standard in analyses of plasma.
7
Internal standard in analyses of urine bile alcohols H. pomutia juice using a method similar to that of Wolthers et al. (22) . After determination of the urinary creatinine concentration, the cholanoids from 2 mL of urine were extracted on a CIS cartridge and then reconstituted in 2 mL of water. After the addition of 100 p L of 5 M sodium acetate buffer, pH 4.7, and 30 p L of glucuronidase/sulfatase, the samples were incubated for 20 h at 37°C. For quantitative analyses, 50 p L of 250 p M methyl deoxycholate was added after thc incubation. The cholanoids were then extracted with a C18 cartridge, eluting with 2 X 5 mL of methanol. The dried eluate was reconstituted in toluene/hexane (1:1, vol/vol) and subjected to chromatography on neutral alumina (as used in the purification of bile acid methyl esters). The TMS ethers of the bile alcohols were prepared and analyzed by GC-MS using the same gas chromatography and mass spectrometry settings as used for bile acids (13, 14) . Urinary bile alcohol profiles from the patient described below were compared with profiles from normal infants, from infants with cholcstatic liver disease of known cause and from three adults with CTX (samples supplied by Dr. B. J. Koopman). Quantitation of urinary bile alcohol concentrations was achieved by comparing peak areas with the area of the internal standard peak.
Analysis of duodenal bile. Duodenal juice was aspirated before and after i.v. injection of cholecystokinin. The bile was analyzed by FAB-MS and by GC-MS after enzymatic deconjugation (14) . Quantitation of bile acid concentrations was achieved by the use of nordeoxycholic acid as internal standard (as for plasma samples).
Case History
The propositus, AA, was the fourth child of healthy unrelated Asian parents. Their first child died at 13 mo, having been jaundiced all his life; their second is a boy who is well; and their third was a still birth. AA was born at term by vaginal delivery. Jaundice was noted at 7 d, and examination revealed hepatomegaly. He was referred for investigation at 9 wk when examination revealed the following: weight, 5.85 kg (90th percentile); head circumference, 40 cm (90th percentile); deep jaundice; and firm liver edge 4 cm from the costal margin in the midclavicular line.
Investigations revealed hemoglobin 10.7 g/dL; reticulocytes 3.2%; film, some crenated cells; prothrombin ratio 1. crcatinine, urea, electrolytes, calcium, and phosphate normal; cholesterol 6.3 mM (normal 1.7-4.4 mM); triglycerides 1.7 mM (normal 0.6-1.9 mM); plasma amino acids normal; a,-antitrypsin phenotype PiMM; galactose-I-phosphate uridyl transfcrase normal; cortisol, thyroid-stimulating hormone, and I.-thyroxine normal; and bone marrow aspirate, no storage cclls. There was no evidence of urinary tract infection, and serologic tests for hepatitis A and B were also negative.
An ultrasound examination showed normal liver parenchyma but a very small gallbladder. Thc right hepatic and common bile ducts were visualized and were not dilated. The portal vein was patent and the spleen measured 7.2 cm. A methyl bromida scan showed no definite evidence of biliary excretion into the bowel. A percutaneous liver biopsy showed a nonspecific hepatitis with giant cells and a few areas of focal bridging necrosis. Thcre was a marked inflammatory cell infiltrate and very marked cholestasis. In view of the severe hepatitis and cholestasis, AA was treated with prednisolone, 10 mg daily (at the age of 0.2 y). Despite this treatment he failed to thrive 011 breast milk, and supplementation with Pregestemil (Mead Johnson, Hoonslow, UK) was advised. Ovcr the next 0.17 y, there was a fall followed by a small rise in serum bilirubin and a small rise in the AST (Fig. 2) . At 0.37 y, treatment with chenodeoxycholic acid (10 mgikgld) was commenced, but over the next 2% wk the bilirubin doubled as did the ALP and, although there was no rise in AST, chenodeoxycholic acid treatment was discontinued at 0.42 y. Over the next 2 wk, the bilirubin continued to rise (to 350 pM), and there was also a marked rise in AST (to 2530 IU/L). Massive firm hepatomegaly (10 cm from the costal margin) was noted. Chenodeoxycholic acid (10 mglkg) was recommenced at 0.47 y, and the bilirubin fell to 260 pM, the AST to 690 IUlL. At this time (0.48 y), pruritus, which had been apparent from 0.3 y, became severe, and treatmcnt with phenobarbitone (2 mg/ kg) was commenccd. At 0.49 y the bile acid therapy was changed to chenodeoxycholic acid (5 mglkgld) plus cholic acid (5 mglkgld). From this point on there was a steady improvement in bilirubin and AST (Fig. 2) . A second liver biopsy performed at 0.52 y confirmed that the deterioration in liver function tests which had been observed between 0.2 and 0.52 y had been accompanied by a deterioration in liver histology; there was an established cirrhosis with cholestasis and active (although reduced) portal inflammation. Pruritus remained a problem, and rifampicin (10 mglkgld) was added to the treatment regimen at 0.52 y. By 0.6 y the bilirubin was normal (18 FM) and the AST o111y mildly elevated (91 IUIL). At 0.71 y, chenodeoxycholic acid therapy was discontinued but cholic acid continued at a dose of 5 mglkgld. The improvement in LFT was maintained when cholic acid, rifampicin, and phenobarbitone were the only drugs in use, and by 0.78 y the bilirubin was normal (8 pM) as was the AST (49 IUIL). The liver was much smaller than at 0.47 y (the edge being palpable 3 cm from the costal margin); the spleen was palpable 1.5 cm from the left costal margin. Pruritus was also considerably better, and weight gain was normal.
When AA was 1.15 y old, a slight rise in bilirubin, AST, and ALP were noted. The dose of cholic acid was increased from 40 to 80 mg/d (8 mglkgld), and the LFT improved again. Despite the normal LFT, a liver biopsy at 1.25 y was markedly abnormal. Portal fibrosis was seen, associated with edema and a cellular infiltrate. There was localized hepatocellular necrosis, gjant cell transformation, and cellular infiltration of the parenchyma. There was evidence of cholestasis (bile pigment in canaliculi). The architecture was disrupted to the point of cirrhosis, there was disruption of the limiting plates, and there was bile duct reduplication. Thus the biopsy suggested an active cirrhosis. Between 1.25 and 3.5 y, AA was treated with cholic acid, 80 mg daily, only (the rifampicin and phenobarbitone having been discontinued). He continued to show normal growth and examination showed no hepatosplenomegaly or stigmata of chronic liver disease. All LFT were normal.
RESULTS
Pretreatment Samples
Plasma cholanoid analysis. The chromatogram obtained from a plasma sample from AA is shown in Fig. 3 (upper trace). Chenodeoxycholic acid and cholic acid were both detectable (peaks 7 and 8), but their concentrations were much lower than in other infants and children with cholestatic liver disease ( Table 2 ). The chromatogram also revealed the presence of four compounds that we have never previously detected in the plasma of children with or without liver diseasepeaks 4, 6, 10, and 11 in Figure 3 . Peak 11 was readily identified by comparison with the reference compound as SP-cholestane-3cr,7a,12cr,25-tetrol. The presence of this compound and the low plasma concentrations of chenodeoxycholic acid and cholic acid were reminiscent of the chromatogram from a 55-y-old lady with CTX (Fig. 3, lower trace) . However, there were other compounds present in the plasma of AA that were not seen in the patient with CTX. Peak 6 produced a mass spectrum identical with the TMS ether of 5P-cholest-24-ene3a,7a,12a-trio1 (17). Peak 4 was an isomer of peak 6 but the mass spectrum had additional major fragment ions of mlz 281 and 371, suggesting a A2%tructure in the side chain; this compound was therefore provisionally identified as SP-cholest- Figure 3 . Total ion currents obtained on GC-MS analysis of plasma from paticnt AA (~cpper trcice) and from a patient with CTX (lower trace). Mass spectra and retention indiccs permitted identilication of pcaks as follows: 1, nordcoxycholic acid (internal standard); 2, cholestanc-3,7,12-trioi; 3, cholesterol (+ some 7a-hydroxycholcsterol in CTX sample); 4, side chain unsaturated cholcstenetriol (?5P-cholest-23-ene-3a,7a,l2a-triol); 5, 5P-cholestanc3a,7a,12a-triol; 6, ?5P-cholcst-24-ene-3a,7a,12a-triol; 7, ehcnodeoxycholic acid; 8, cholic acid; 9, 7cu,l2a-dil1ydroxyc11olest-4-e11e-3-onc; 10, SPcholestane-3~,7a,12a,24~-tetrol; 11, iP-cliolcstane-3a,7a,l2a,25-tctrol. Arzalysis of urirzary cholarzoids. The negative ion FAB mass spectrum of urine from AA is shown in Figure 4b , alongside the FAB mass spectrum of urine from an infant with cholestatic liver disease due to cytomegalovirus hepatitis (Fig. 4a) and the FAB mass spectrum of the urine from a patient with CTX (Fig.  4c) . The postulated origins of the major ions are indicated in the figure legend; these are in part based on the results of the GC-MS analysis (given below). The largest peak in the spectrum from the urine of AA (Fig. 4b) had a massicharge ratio of 61 1-compatible with the quasimolecular ( M -H ) ions of cholestanctetrol glucuronides. The second largest peak was of m/z 627, suggestive of cholestancpentol glucuronides. The presence of large amounts of bile alcohol glucuronides in the urinc with undetectable bile acid cxcretion was similar to the pattern seen in the urine of an adult with CTX (Fig. 4c) . By contrast, 60 infants with severe cholestatic liver disease showed a pattern similar to that seen in Figure 4a ; the bile acid excretion was much greater than the bile alcohol excretion and the major bile alcohol was usually 27-nor-SP-cholestanepentol glucuronidc (m/z 613). Analysis of urinc from 90 normal infants by FAB-MS revealed only small amounts of bile acids and of bile alcohol glucuronides (close to the limit of detection of the method); the peak heights produced by the bile acids and bile alcohols were similar.
Analysis of the urine from AA by GC-MS after digestion with glucuronidase/sulfatase (Fig. 5) revealed that the major bile alcohol present was 5P-cholestane-3a,7a,l2~,24S,25-pent01 (peak D); excretion of this compound was 10 times that of the 24R isomer (peak C). In samples from three patients with CTX, urinary excretion of the 3a,7a,12a,24S,25-pentol was only twice that of the 24R isomer, and, in any ease, excretion of the 3a,7a,12a,24,25-pentols was appreciably less than that of other SP-cholestane-pentols, in particular 3,7,12,22,25-pentols and 3,7,12,23,25-pentols. 5P-Cholestane-3a,7a,12a,25-tetrol was a major component of the urinary bile alcohol profile of both AA (Fig. 5, peak B) and the CTX patients. 5P-Cholestane-3cu,7a,12a, 245-tetrol (Fig. 5, peak A) was a major component in AA but not in the CTX patients. Table 3 shows the results of quantitation of urinary excretion of bile alcohols in AA, in normal infants and in infants with eholestasis. The excretions of 5P-cholestane-3a,7a,12a,245-tetrol, -3a,7a,12cr, 25-tetrol, and -3a,7a,12a,24S,25-pentol were orders of magnitude greater than in both normal and cholestatic controls. The excretion of 27-nor-5P-cholestane-3a,7a,l2a,24,25-pentol was not increased. 
Analysis of duodenal bile. Concentrations of bile acids in AA's duodenal juice after i.v. injection of cholecystokinin were reduced 1000-fold: chenodeoxycholic acid 0.29 p M (controls 0.3-6.1 mM); cholic acid 1.12 p M (controls 2.1-12.7 mM). The pre-cholecystokinin concentrations were similarly reduced. The chromatogram from AA showed some other unusual features. There was a sizeable peak with the retention time of cholesterol (as was the case with chromatograms from other bile samples), but mass spectrometry indicated that, in the case of AA, this peak contained a substantial amount of 7a-hydroxycholesterol (unlike the control samples). The chromatogram from A A also showed a peak due to 7P-hydroxycholesterol (not detected in controls) and a series of small peaks whose spectra suggested that they were side chain unsaturated bile alcohols that were not fully identified.
Follow-up Samples
Plasma cholanoid projile. Treatment with chenodeoxycholic acid, 10 mglkgld, when AA was aged 0.37 y was associated with a dramatic rise in plasma chenodeoxycholic acid concentration with no sign of improvement in the cholestasis (Fig. 2) . The plasma concentration of chenodeoxycholic acid and that of cholic acid were directly related to what was being given orally until AA was 0.55 y when, with no change in the bile acid therapy, plasma bile acid concentrations fell dramatically; this fall coincided with a drop in the AST and bilirubin, indicating an improvement in the cholestatic liver disease. While AA was being treated with cholic acid alone subsequently, the plasma chenodeoxycholic acid concentration was subnormal (1.2, 0.5 pM) and the cholic acid only slightly elevated (15, 7.1 pM). The effect of bile acid therapy on plasma bile alcohol concentrations is shown in Figure 2 (bottom graph). The improvement in LFT was associated with a fall in the plasma concentrations of both 5P-cholestane3a,7a,12a,25-tetrol and 5P-cholest-24-en-3a,7~~,12a-triol.
The urinary excretion of bile alcohol glucuronides also fell (data not shown).
DISCUSSION
The infant described in this report had low concentrations of bile acids in his duodenal bile, and despite his cholestasis he also had low concentrations in plasma and urine. This suggested a major defect in bile acid synthesis. The excretion in the urine of large amounts of bile alcohols containing the cholic acid nucleus but an 8-carbon side chain indicated that the defect affected a reaction in the conversion of the cholesterol side chain to the bile acid side chain.
Our current view of cholesterol side chain oxidation is that two alternative pathways exist (9) . The first involves hydroxylation in the C-27 position (which occurs in the mitochondria), further oxidation to a C,, bile acid, and then P-oxidation in the peroxisomes. The second pathway starts with C-25 hydroxylation of 5P-cholestane-3a,7a,12a-triol (which occurs in the microsomes) and continues with a second hydroxylation that produces 5P-cholestane-3a,7a,12a,24(S)25-pentol. The 24(S)-pentol is cleaved to produce cholic acid and acetone; a 24-ketone may be an intermediate in this pathway (10) (Fig. 1) .
The major cholanoid in the urine of our patient was 5P-cholestane-3a,7a,l2a,24(S),25-pentol. Therefore the most likely site of the defect was in the cleavage of this pentol. Proof that this was indeed the defect is unfortunately lacking; we were unsuccessful in our attempts to scale down the assays described by Shefer et al. (10) so that they could be used on a few milligrams of liver biopsy. Without proof of the exact site of the defect from enzymology/DNA analysis, we have to consider other possibilities. We know from studies of CTX that a defect in an early step in the C-27 hydroxylase pathway can lead to diversion of 5P-cholestane-3a,7a,12a-triol into the C-25 hydroxylase pathway with the result that the major urinary cholanoids are pentols with hydroxyl groups in the 3a-, 7a-, 12a-, and C-25 positions. Presumably the 25-hydroxylase enzyme can cope with the increased flux but subsequent steps in the pathway to cholic acid are overloaded; hence, the 5P-cholestane-3a,7aj12a,25-tetrol accumulates and undergoes further hydroxylation reactions (e.g. at C-22 and C-23).
It seems most unlikely that our patient has 27-hydroxylase deficiency (i.e. a variant of CTX). His major problcm has been cholestatic liver disease of neonatal onset; cholestatic liver disease has never been described in CTX. Furthermore, in CTX, the major urinary bile alcohols are C22,C25 pentols and C23,C25 pentols whereas in our patient the C24(S),C25 pentol predominated. In retrospect, it would have been useful to measure plasma 26-hydroxycholesterol in our patient. Plasma 26-hydroxysterol is low in patients with CTX and is a direct indication of reduced activity of the sterol 27-hydroxylase (which hydroxylates cholesterol as well as intermediates such as 5P-cholestane-3a,7a,12a-triol).
It also seems unlikely that our patient has a deficiency of an enzyme in the 27-hydroxylase pathway distal to 5P-cholestane3a,7a,12a,27-tetroI. This would be expected to produce substantial accumulation of the tetrol or of C,, bile acids; these would have been detected by our analyses and were not present.
Thus the available evidence supports the thesis that our patient has a deficiency in the side chain cleavage step(s) of the 25-hydroxylase pathway. If so, the severe deficiency of primary bile acids documented in the first year of life suggests that either the 25-hydroxylase pathway is the major route for bile acid synthesis at this age or accumulation of bile alcohols blocks reactions in the 27-hydroxylase pathway. So far, the evidence has tended to indicate that the 25-hydroxylase pathway is relatively unimportant in man; however, this evidence needs to be critically examined. Important studies by Kasc et ill. (25) have used an experiment of nature to try to delineate the relative contributions of the two pathways of side chain oxidation in infancy. This relied upon the fact that the 27-hydroxylase pathway involves the 0-oxidation of C,, bile acids in the peroxisomcs. Patients with Zellwcger syndrome lack peroxisomes, and for this reason the 27-hydroxylase pathway is blocked. Kasc et 01. (25) found that the rate of conversion of 5P-cholcstane-3a,7a,12a-triol to cholic acid in an infant with Zellwegcr syndrome was 15-20% of that seen in normal subjects, and the overall synthesis rate of cholic acid was 10% of normal. They concluded that when the 27-hydroxylase pathway is blocked cholic acid synthesis is severely inhibited, indicating that the 27-hydroxylase pathway is the major pathway for cholic acid synthesis. However, it should be remembered that patients with Zellwegcr syndromc have a plethora of biochemical abnormalities that stem from their inability to assemble normal peroxisomes. For exarnple they lack sterol-carrier protein-2 (nonspecific lipid transport protcin), which is important for the activity of cholesterol 7a-hydroxylase-the rate-limiting step in bile acid synthesis (26, 27) . Furthermore, most patients (including the infant studied by Kasc et (11.) havc elevated transaminases, and most develop hcpatic fibrosis or cirrhosis. It is well known that cholic acid synthesis rates arc easily depressed by acute or chronic hepatocytc damage (28); this is not due to a problem in the peroxisomes because C27 bilc acids do not accumulate. If, instead of looking at patients with disorders of peroxisome biogcncsis, we look at patients with defects of single enzymes in the peroxisomal 0-oxidation pathway (e.g. trifunctional protcin deficiency, peroxisomal thiolase dcficiency) a different pattern emcrgcs (2, 14) . These paticnts accumulate C,, bilc acids (and very long chain fatty acids), but they do not have some of the other biocllemical abnormalities of the biogenesis defects. Standard liver function tests and liver histology are virtually normal. Cholic and chcnodeoxycholic acid are readily detectable in duodenal bile and plasma and there is no cholcstasis. This suggests that it is possible to have a defect of the 27-hydroxylase pathway without severely disrupted bilc acid synthesis. By contrast the patient described in this report, who probably has a defect of the 25-hydroxylase pathway, has evidence of markedly reduced bilc acid synthesis; this would be compatible with the 25-hydroxylase pathway being the major pathway for side chain oxidation in infancy.
The cause of liver damage in inborn errors of bile acid synthesis is uncertain. Two mechanisms that havc been considered are I) loss of the bilc acid-dependent component of bilc flow leading to hcpatic retention of toxic compounds normally excreted in bilc and 2) direct toxicity of intermediates in bilc acid synthesis or compounds derived from them. Oral bile acid therapy has been proposed on the basis that it will both fuel bile flow and reduce synthesis of toxic intermediates (by inhibition of cholesterol 7a-hydroxylase). However, trcatment with chenodeoxycholic acid requires extreme caution because an excess of this hvdro~hobic bile acid can lead to deterioration in liver chenodeoxycholic acid therapy. In a fourth patient with very severe cholestasis and hepatocyte damage, the bilirubin and AST rose when treatment with chenodeoxycholic acid was instituted and improved slowly only when the regimen was changed to a combination of cholic acid and chenodcoxycholic acid (2). The patient described in this study also had severe cholestasis and hepatocyte damage. When chenodeoxycholic -acid trcatment was commenced, there appeared to be an initial exacerbation of cholestasis, but when trcatment with chenodeoxycholic and cholic acids was recommenced, there was a steady improvement with normalization of LFT in 4 mo. Biopsies covering 9 mo of treatment showed a reduction in the amount of hcpatocellular necrosis and portal inflammation but a progression to cirrhosis despite treatment. Clinically the patient is extremely well at the age of 3% y-a favorable outcome compared with that of his affccted sibling who died at the age of 13 mo. 
